Literature DB >> 9093140

A medical approach to management of spontaneous abortion using misoprostol. Extending misoprostol treatment to a maximum of 48 hours can further improve evacuation of retained products of conception in spontaneous abortion.

T Chung1, P Leung, L P Cheung, C Haines, A M Chang.   

Abstract

BACKGROUND: To compare a 48 hour non surgical policy in the management of spontaneous abortion with a policy of routine, universal uterine curettage.
METHODS: A prospective, observational study on 354 women admitted to hospital with spontaneous abortion. Of these, 225 who had retained products of conception were treated with misoprostol for up to 48 hours after 101 were excluded because they had an empty uterus on transvaginal scan (TVS) and another 28 women because they were unsuitable for conservative management. Follow-up was conducted over a 3 week period to assess morbidity. A reference group of 137 women, all of whom had an evacuation of retained products of conception (ERPC) as a routine after they had a TVS documenting retained products of conception (POCs), was used for comparison.
RESULTS: Evacuation of the uterus occurred within 24 hours in 107 women and in 148 at 48 hours after misoprostol treatment was started. There were three uterine curettages up to 14 days after discharge from hospital for persistent bleeding and two cases of pelvic infection. An ectopic pregnancy was diagnosed at follow-up in one woman. In the reference group, there were nine women who had complications, four requiring another ERPC and five had infection, an overall complication rate of 6.6% in the reference group and 1.7% in the protocol treatment group.
CONCLUSION: A 48 hour regimen using transvaginal ultrasound and misoprostol for the management of spontaneous abortion was successful in avoiding surgery in 249 out of a possible 354 (70.6%) women with spontaneous abortion, with a low rate of subsequent morbidity.

Entities:  

Keywords:  Abortion, Spontaneous; Asia; Biology; Clinical Research; Comparative Studies; Curettage--therapeutic use; Developing Countries; Diseases; Eastern Asia; Endocrine System; Hong Kong; Misoprostol--therapeutic use; Obstetrical Surgery; Physiology; Pregnancy Complications; Products Of Conception, Retention; Prostaglandins; Prostaglandins, Synthetic; Research Methodology; Research Report; Studies; Surgery; Treatment; Ultrasonics

Mesh:

Substances:

Year:  1997        PMID: 9093140

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  6 in total

1.  Ultrasonography may have role in assessing spontaneous miscarriage.

Authors:  A Weeks; G Alia
Journal:  BMJ       Date:  2001-09-22

2.  Endometrial thickness after misoprostol use for early pregnancy failure.

Authors:  M D Creinin; B Harwood; R S Guido; M C Fox; J Zhang
Journal:  Int J Gynaecol Obstet       Date:  2004-07       Impact factor: 3.561

3.  Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial).

Authors:  J Trinder; P Brocklehurst; R Porter; M Read; S Vyas; L Smith
Journal:  BMJ       Date:  2006-05-17

4.  Factors related to successful misoprostol treatment for early pregnancy failure.

Authors:  Mitchell D Creinin; Xiangke Huang; Carolyn Westhoff; Kurt Barnhart; Jerry M Gilles; Jun Zhang
Journal:  Obstet Gynecol       Date:  2006-04       Impact factor: 7.661

5.  Acceptability and safety profile of oral and sublingual misoprostol for uterine evacuation following early fetal demise.

Authors:  Devendra Singh Kushwah; Beenu Kushwah; Mohd Tariq Salman; V K Verma
Journal:  Indian J Pharmacol       Date:  2011-05       Impact factor: 1.200

6.  Instability of misoprostol tablets stored outside the blister: a potential serious concern for clinical outcome in medical abortion.

Authors:  Veronique Berard; Christian Fiala; Sharon Cameron; Teresa Bombas; Mirella Parachini; Kristina Gemzell-Danielsson
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.